Back to search

Boston University

PCSK9 inhibitors as a therapy for hypercholesterolemia

Abstract

dc:description.abstract

The recent discovery of proprotein convertase subtilisin/kexin type 9 as a protein that increases LDL-cholesterol has lead researchers to investigate it as a target for cholesterol-lowering medication. New options for cholesterol-lowering therapies are of particular importance for individuals, such as those with familial hypercholesterolemia and statin intolerance, who are unable to achieve recommended values through other means. Currently, two monoclonal antibodies inhibiting PCSK9 are approved for use; these monoclonal antibodies work well in conjunction with other medications for hypercholesterolemia, such as statins or ezetimibe, and are equivalent in efficacy with high dose statins. Investigation of PCSK9 inhibitors through siRNA may provide additional mechanisms for lowering cholesterol in the future.

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
masters
Discipline thesis:degree_discipline
Medical Sciences
Grantor
Boston University
Year dc:date.issued
2016

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Nofal, Maia

Subjects

dc:subject × 1

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/17002

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Nofal, Maia. PCSK9 inhibitors as a therapy for hypercholesterolemia. masters thesis, Boston University, 2016. https://hdl.handle.net/2144/17002